Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Investing Activities: 2012-2024

Historic Cash from Investing Activities for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to $131.7 million.

  • Rocket Pharmaceuticals' Cash from Investing Activities rose 18.62% to $93.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.5 million, marking a year-over-year increase of 2.43%. This contributed to the annual value of $131.7 million for FY2024, which is 234.30% up from last year.
  • According to the latest figures from FY2024, Rocket Pharmaceuticals' Cash from Investing Activities is $131.7 million, which was up 234.30% from -$98.1 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Cash from Investing Activities ranged from a high of $131.7 million in FY2024 and a low of -$98.1 million during FY2023.
  • For the 3-year period, Rocket Pharmaceuticals' Cash from Investing Activities averaged around -$11.9 million, with its median value being -$69.3 million (2022).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Cash from Investing Activities tumbled by 467.72% in 2022, and later soared by 234.30% in 2024.
  • Rocket Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$96.6 million in 2020, then spiked by 119.52% to $18.9 million in 2021, then crashed by 467.72% to -$69.3 million in 2022, then crashed by 41.46% to -$98.1 million in 2023, then spiked by 234.30% to $131.7 million in 2024.